



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304415117US
Express Mail Label Number

September 6, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1639

HUANG ET AL.

Examiner: LIU, SUE XU

APPLICATION NO: 10/501,035

FILED: MAY 02, 2005

FOR: IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDI
FOR PREDICTING ACTIVITY OF COMPOUNDS THAT
INTERACT WITH PROTEIN TYROSINE KINASES AND/OR
PROTEIN TYROSINE KINASE PATHWAYS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: September 6, 2007


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652



Substitute for form 1449/PTO		PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i>		COMPLETE IF KNOWN	
		Application Number	10/501,035
		Filing Date	05/02/2005
		First Named Inventor	FEI HUANG
		Art Unit	1639
		Examiner Name	LIU, SUE XU
		Attorney Docket Number	D0185 US PCT
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Beck, et al., "BMP-induced growth suppression in colon cancer cells is mediated by p21 ^{WAF1} stabilization and modulated by RAS/ERK", Cellular Signalling, Vol. 19, pp. 1465-1472 (2007)	
	AB	Wen, et al., "Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas", Oncogene, Vol. 25, pp. 2666-2673 (2006)	
	AC	Hardwick, et al., "Bone Morphogenetic Protein 2 Is Expressed by, and Acts Upon, Mature Epithelial Cells in the Colon", Gastroenterology, Vol. 126, pp. 111-121 (2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant